Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year

Oct 15, 2010, 17:00 ET from Precision Therapeutics

PITTSBURGH, Oct. 15 /PRNewswire/ -- Precision Therapeutics announced today that its President and Chief Executive Officer Sean McDonald was recognized as CEO of the Year by the Pittsburgh Technology Council.

(Photo: )

(Photo: )

The Tech 50 award recognizes the accomplishments of 50 of southwestern Pennsylvania's most successful entrepreneurs whose innovation and creativity have been used to strategically enhance the ideals and growth of their organization as well as the community and greater region. McDonald was selected by an independent panel of technology experts and the category awards were presented on October 14, 2010, at the Hilton Downtown Pittsburgh.

Sean joined Precision in 2001 and has since dedicated his career to developing innovative technologies with the goal of helping physicians to select customized treatment to meet the individual needs of each cancer patient. He most recently led Precision to earn a first place ranking as an industry leader in the health care division in the Pittsburgh region.  Because of Sean's passion, leadership and vision, Precision Therapeutics remains at the forefront of personalized diagnostics and research for individualized cancer therapy, with nearly 32,000 patient specimens sent for ChemoFx® testing and 18 active clinical trials.

About Precision Therapeutics

Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients. As leaders in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer.

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy.  Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician.

For more information, please visit

SOURCE Precision Therapeutics